Immunotec Mourns Passing of Senior VP - Dr. Wulf Droge, Ph.D.
December 22 2010 - 5:19PM
Marketwired
It is with deep sadness that Immunotec Inc. (TSX VENTURE: IMM)
announces the death of its colleague, leader and friend, Dr. Wulf
Droge, Senior Vice- President, Research & Development.
Dr. Droge, was a world-renowned scientist with more than forty
years in basic and clinical research and participation in more than
280 publications, in the areas of redox modulation and aging. After
completing a postdoctoral fellowship at the Max Planck Institute
and at Harvard University, Dr. Droge spent 3 years as a scientific
member at the renowned Basel Institute of Immunology and 29 years
as professor of cell biology at the University of Heidelberg as
well as department head at the National Cancer Research Center of
Germany (Deutsches Krebsforschungszentrum).
After his retirement from the academic sector, he joined
Immunotec in 2005 as head of Research and Development, and he
contributed greatly to promoting the benefits of cysteine
supplementation with Immunocal®. He was the architect of the
Immunocal® Platinum product, one of the Company's flagship
products.
"We wish to express our most sincere condolences to his wife and
to their daughter", said James A. Northrop, President and CEO of
Immunotec Inc. "The scientific community has lost a great leader
and Immunotec owes Wulf a tremendous debt of gratitude for his
contributions over the years".
About Immunotec Inc.
Immunotec is a Network Marketing Company involved in the direct
selling of scientifically validated natural health products and
dietary supplements. The Company offers a lucrative business
opportunity to its independent distributors. This business model
provides Immunotec's network of people with an opportunity to earn
a steady and recurring income, directly based on their level of
involvement and performance. Individual distributors build their
business by conveying product information and selling product to
customers and by building teams of distributors to expand
geographic penetration and market coverage to larger populations of
customers.
Headquartered with manufacturing facilities near Montreal,
Canada, the Company also subcontracts certain distribution
logistics and capacity to support its activities in the United
States, Europe, Mexico and The Caribbean.
The Company files its consolidated financial statements, its
management and discussion analysis report, its press releases and
such other required documents on the SEDAR database at
www.sedar.com and on the Company's website at www.immunotec.com.
The common shares of the Company are listed on the TSX Venture
Exchange under the ticker symbol IMM.
"The TSX Venture does not accept responsibility for the adequacy
or accuracy of this release."
Contacts: Immunotec Inc. Patrick Montpetit VP and Chief
Financial Officer 450-510-4527
International Metals Min... (TSXV:IMM)
Historical Stock Chart
From Nov 2024 to Dec 2024
International Metals Min... (TSXV:IMM)
Historical Stock Chart
From Dec 2023 to Dec 2024